Solventum Corporation $SOLV is Investment Management Associates Inc. ADV’s 7th Largest Position

Investment Management Associates Inc. ADV boosted its stake in shares of Solventum Corporation (NYSE:SOLV) by 10.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 258,949 shares of the company’s stock after acquiring an additional 24,116 shares during the quarter. Solventum comprises 5.6% of Investment Management Associates Inc. ADV’s investment portfolio, making the stock its 7th biggest holding. Investment Management Associates Inc. ADV owned 0.15% of Solventum worth $18,903,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. Deseret Mutual Benefit Administrators lifted its holdings in shares of Solventum by 78.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after purchasing an additional 163 shares during the period. CYBER HORNET ETFs LLC purchased a new position in Solventum during the 2nd quarter worth $28,000. IMG Wealth Management Inc. acquired a new stake in shares of Solventum in the 2nd quarter worth $31,000. MUFG Securities EMEA plc acquired a new stake in shares of Solventum in the 2nd quarter worth $31,000. Finally, State of Wyoming purchased a new stake in shares of Solventum in the second quarter valued at about $33,000.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Zacks Research cut shares of Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Mizuho set a $100.00 target price on Solventum and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a report on Saturday. BTIG Research raised Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Tuesday, December 2nd. Finally, KeyCorp upgraded Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 price objective for the company in a research report on Monday, January 26th. Seven research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $90.83.

Solventum Price Performance

SOLV stock opened at $80.44 on Wednesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $88.20. The stock’s 50 day moving average price is $80.47 and its 200 day moving average price is $76.03. The firm has a market cap of $13.95 billion, a P/E ratio of 9.27, a PEG ratio of 7.17 and a beta of 0.35.

Solventum announced that its board has initiated a stock repurchase program on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 7.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.